Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › myocardial ischemia

Myocardial ischemia

Subtypes of Myocardial ischemia

Coronary Artery Disease 113 Myocardial Infarction 45 ST-Segment Elevation Myocardial Infarction 11 Angina 6 ST-Elevation Myocardial Infarction 6 Cardiogenic Shock 5 Multivessel Coronary Artery Disease 5 Multivessel Disease 5 Coronary Atherosclerosis 3 Left main coronary artery disease 3 Non-ST-segment elevation myocardial infarction 3 Non-ST-elevation myocardial infarction 2 Coronary Artery Stenosis 1 Left Main Disease 1 MINOCA 1 NSTEMI 1 STEMI 1 Microvascular angina 0

184 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for myocardial ischemia

58 trials tracked for myocardial ischemia: 15 in phase 3 or 4 and 2 with published results. The most-cited published study has 63 citations.

58Trials tracked
15Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 8 Phase 3 7 Phase 2 12 Other / NA 31
  1. Phase 4 ISCHEMIA-Chronic Kidney Disease Trial Completed · 63 cited
  2. Phase 3 Glutamate for Metabolic Intervention in Coronary Surgery Completed · 46 cited
  3. Phase 4 XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort Completed
  4. Phase 4 XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT) Completed
  5. Phase 4 CES1 Carriers in the PAPI Study Completed
  6. Phase 4 Statin Therapy for Ischemic and Nonischemic Cardiomyopathy Completed
Show 44 more trials
  1. Phase 4 Effect of Ranolazine on Myocardial Perfusion Assessed by Serial Quantitative Exercise SPECT Imaging Completed
  2. Phase 4 Responses of Myocardial Ischemia to Escitalopram Treatment Completed
  3. Phase 4 XIENCE V: SPIRIT WOMEN Sub-study Completed
  4. Phase 3 SPIRIT PRIME Clinical Trial Completed
  5. Phase 3 METhotrexate Therapy Effects in the Physical Capacity of Patients With ISchemic Heart Failure (METIS Trial) Completed
  6. Phase 3 SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS) Completed
  7. Phase 3 An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome Completed
  8. Phase 3 Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer Completed
  9. Phase 3 EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED) Completed
  10. Phase 2 Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention Completed
  11. Phase 2 ACT34-CMI -- Adult Autologous CD34+ Cells Completed
  12. Phase 2 Evaluation of the Safety and Effectiveness of the CorPath 200 System in Percutaneous Coronary Interventions (PCI) Completed
  13. Phase 2 PK and Tolerability of IV and Oral CK-1827452 in Patients With Ischemic Cardiomyopathy and Angina Completed
  14. Phase 2 Trial to Assess the Safety and Effects of Vorapaxar in Japanese Subjects With Acute Coronary Syndrome (P04772; MK-5348-016) Completed
  15. Phase 2 Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome Completed
  16. Phase 2 The Effects of Intravenous Heme Arginate on Heme Oxygenase-1 Expression (HO-1) and Oxidative Stress in the Human Heart Completed
  17. Phase 2 Absolute Quantification of Coronary Flow Reserve by Stress Perfusion MRI Completed
  18. Phase 2 Custodiol-HTK (Histidine-tryptophan-ketoglutarate) Solution as a Cardioplegic Agent Completed
  19. Phase 2 Ranolazine Mediated PVC Reduction in Ischemic Heart Disease Completed
  20. Phase 2 Pilot Study of Atorvastatin for Orthopedic Surgery Patients Completed
  21. Phase 2 Microvascular Coronary Disease In Women: Impact Of Ranolazine Completed
  22. N/A A Clinical Evaluation of the XIENCE PRIME Small Vessel Everolimus Eluting Coronary Stent System in Japanese Population Completed
  23. N/A Stress CMR Perfusion Imaging in the United States (SPINS) Study Completed
  24. N/A AngioSculpt® Coronary Bifurcation Study Completed
  25. N/A ABSORB EXTEND Clinical Investigation Completed
  26. N/A XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval, Single-Arm Study Completed
  27. N/A Extracellular Matrix Marker of Arrhythmia Risk (EMMA) Completed
  28. N/A International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) Completed
  29. N/A Regadenoson Combined With Symptom-Limited Exercise in Patients Undergoing Myocardial Perfusion Imaging Completed
  30. N/A Scoreflex NC - Scoring PTCA Catheter Completed
  31. N/A Sapphire II PRO US Clinical Study Completed
  32. N/A Secondary Event Prevention Using Population Risk Management After PCI and for Anti-Rheumatic Medications Completed
  33. N/A Impact of a Corrie Cardiac Rehabilitation Program Completed
  34. N/A RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 DES in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries Completed
  35. N/A XIENCE V/PROMUS Everolimus-Eluting Stent System Post-marketing Surveillance Protocol for Japan Completed
  36. N/A Pressure Guidewire System Multi-center, Prospective, Self-Control, Clinical Trial Completed
  37. N/A RESOLUTE Japan - The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent Completed
  38. N/A XIENCE V® Everolimus Eluting Coronary Stent System USA Post-Approval Study (XIENCE V® USA Long Term Follow-up Cohort) Completed
  39. N/A AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population Completed
  40. N/A XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS) Completed
  41. N/A Data Analyses for Ancillary WISE Femhrt Hormone Replacement Study Completed
  42. N/A Absorb GT1 Japan PMS Completed
  43. N/A Safety and Effectiveness of the Orsiro Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions Completed
  44. N/A XIENCE PRIME Japan Post-Marketing Surveillance (PMS) Completed

Showing the 50 most-cited and recently-updated of 58 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

Myocardial ischemia: current evidence & treatments

In patients with myocardial ischemia, several interventional strategies have been evaluated. For unprotected left main coronary artery disease, IVUS-guided PCI showed no significant difference compared to angiography-guided PCI for the primary composite outcome of stroke, myocardial infarction, revascularization, or death (HR 1.11; 95% CI 0.87-1.42; P=0.40) 1. In NSTEMI patients with multivessel disease, complete revascularization demonstrated a high probability of benefit over culprit-only revascularization for the composite endpoint of all-cause death, nonfatal MI, repeat revascularization, and stroke 9. For STEMI with multivessel disease, staged revascularization showed no significant difference versus immediate revascularization for major adverse cardiovascular events 14. In severe aortic stenosis patients with CAD, PCI before TAVR did not significantly reduce all-cause mortality or cardiovascular death but lowered revascularization needs at the cost of increased bleeding 22.

Pharmacological and non-pharmacological interventions also show promise. Colchicine reduced major adverse cardiovascular events and myocardial infarction in coronary artery disease without increasing serious adverse events 8. Inclisiran plus usual care improved LDL-C goal attainment after acute coronary syndrome, with 74.6% achieving LDL-C <70 mg/dL at Day 90 vs 26.6% with usual care (OR 10.84) 25. High-intensity interval aerobic exercise improved brachial flow-mediated dilation in coronary artery disease and heart failure 3. Baduanjin exercise improved outcomes in acute MI patients undergoing PCI 12. Additionally, pre-infection COVID-19 vaccination was associated with lower cardiovascular and cerebrovascular event risks in SARS-CoV-2 infected individuals 20.

Biomarkers and risk factors are also relevant. Higher pan-immune-inflammation value (PIV) was linked to worse outcomes after PCI for ACS (adjusted HR 1.65 for MACE; HR 3.51 for all-cause mortality) 4. Serum resistin levels increased progressively with worsening severity of coronary heart disease and acute MI 16. Breast arterial calcification on mammography predicted higher cardiovascular event risk in women (HR 1.82) 13 and was linked to increased cardiovascular mortality 19. Pre-transplant CAD increased all-cause mortality (HR 1.68) and post-transplant cardiovascular events in kidney recipients 2. Polygenic scores were associated with atherosclerosis and ischemic heart disease in Russian populations 7.

Key drugs in the evidence

everolimus 1 sirolimus 1

Latest findings

AI-generated synthesis of 15 cited studies, updated Jun 12, 2026. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis finds 2% mean prevalence of class 1 revascularization indications in prekidney transplant CAD screening
Cardiology Meta-analysis
Meta-analysis finds 2% mean prevalence of class 1 revascularization indications in prekidney transplant CAD screening Pre-kidney transplant heart screening rarely finds severe blockages needing immediate surgery
A meta-analysis of 44 prekidney transplant screening studies found a mean 2% prevalence of American Heart Association class 1 indications fo…
Most people screened before kidney transplants do not have severe heart blockages requiring immediate surgery, according to a review of 44 s…
Apr 2, 2026
Higher vs lower heparin dosing for elective PCI tested in cluster randomized trial design
Cardiology RCT
Higher vs lower heparin dosing for elective PCI tested in cluster randomized trial design Trial will compare two heparin doses for elective heart procedures
A cluster randomized crossover trial design paper outlines a study comparing higher-dose (100 units/kg) versus lower-dose (70 units/kg) unfr…
A new trial will test if a lower dose of heparin works as well as the standard amount for patients having elective heart procedures in Ontar…
Apr 2, 2026
Optimism training improves psychological outcomes but shows uncertain biomarker effects in stable CAD patients
Cardiology RCT
Optimism training improves psychological outcomes but shows uncertain biomarker effects in stable CAD patients Can learning optimism help your heart? A small study finds mixed results
A randomized controlled trial of 61 outpatients with stable coronary artery disease found that an eight-week optimism training program signi…
An eight-week optimism class improved mood for heart patients, but the study found no clear link to lowering blood proteins that drive arter…
Apr 2, 2026
Retrospective study identifies five predictors for hypokalemia in STEMI patients
Cardiology Cohort
Retrospective study identifies five predictors for hypokalemia in STEMI patients Can a simple checklist predict dangerous potassium drops after a major heart attack?
A retrospective observational cohort study of 320 STEMI patients at a single Chinese hospital identified five independent predictors for hyp…
A new checklist using five simple signs can predict dangerous potassium drops that trigger deadly heart rhythms after a major heart attack.
Frontiers Apr 1, 2026
Stratified MINOCA Tx improves angina status at 12 months vs standard care in PROMISE trial
Cardiology RCT
Stratified MINOCA Tx improves angina status at 12 months vs standard care in PROMISE trial For heart attacks with clear arteries, does personalized treatment help? New trial shows it improves chest pain
In the PROMISE RCT (n=92), stratified treatment for MINOCA significantly improved angina status at 12 months vs standard care (mean SAQSS di…
Patients with heart attacks and clear arteries got better chest pain and quality of life after doctors found and treated the specific cause …
Mar 30, 2026
Phase 3 trial of milvexian for ACS prevention completes enrollment
Cardiology Phase III
Phase 3 trial of milvexian for ACS prevention completes enrollment Can a new drug help prevent heart attacks and strokes after a serious heart event?
The LIBERATE trial, a Phase 3 study, has completed enrollment of 14,194 participants with a recent acute coronary syndrome to evaluate if mi…
A new drug called milvexian is being tested to see if it lowers the risk of death, heart attack, or stroke after a serious heart event.
CT.gov Mar 30, 2026
Phase 2 trial tests pre-hospital glucocorticoid pulse in STEMI patients undergoing primary PCI
Cardiology Phase II
Phase 2 trial tests pre-hospital glucocorticoid pulse in STEMI patients undergoing primary PCI Phase 2 trial tests steroid pulse for heart attack patients before hospital arrival
A phase 2 randomized controlled trial enrolled 530 STEMI patients treated with primary PCI to test single-dose glucocorticoid pulse therapy …
A new trial tested giving a single steroid dose in ambulances before heart attack patients reach the hospital to reduce permanent heart dama…
CT.gov Mar 30, 2026
Phase 2 pilot study evaluates ticagrelor monotherapy safety after stenting for acute MI
Cardiology Phase II
Phase 2 pilot study evaluates ticagrelor monotherapy safety after stenting for acute MI Can a single blood thinner prevent heart attacks after stent placement?
A single-center, single-arm, prospective phase II pilot study of 200 patients assessed the initial safety of ticagrelor monotherapy after co…
A new pilot study tests if one blood thinner alone can safely prevent heart attacks and stent clots after stent placement for heart attack p…
CT.gov Mar 30, 2026
Colchicine reduces total plaque burden but not low attenuation plaque in stable CAD patients
Cardiology RCT
Colchicine reduces total plaque burden but not low attenuation plaque in stable CAD patients Can a cheap anti-inflammatory drug slow heart disease? It might help reduce plaque buildup
In the EKSTROM RCT (n=84), low-dose colchicine (0.5 mg/day) did not significantly reduce low attenuation plaque volume (median change 0.1 vs…
A cheap anti-inflammatory drug called colchicine may help slow total plaque buildup in arteries for people already managing stable heart dis…
Mar 30, 2026
Increased LV mass linked to discordant stress CMR/ICA results via microvascular resistance
Cardiology RCT
Increased LV mass linked to discordant stress CMR/ICA results via microvascular resistance Why do heart tests sometimes disagree? A thicker heart muscle might be the surprising reason
In patients with suspected obstructive CAD, left ventricular mass (LVM) was higher in those with abnormal stress CMR vs.
A thicker heart muscle can sometimes confuse heart tests, making a normal angiogram look falsely normal even when a problem exists.
Mar 30, 2026
Accelerated stress CMR non-inferior to standard protocol, saves 24 minutes per scan
Cardiology RCT
Accelerated stress CMR non-inferior to standard protocol, saves 24 minutes per scan Can a faster heart scan find blocked arteries just as well as the standard test?
In a prospective RCT of 150 patients with suspected angina, an accelerated stress-only CMR protocol was non-inferior to a standard stress-re…
A faster heart scan takes 24 minutes less than the standard test and finds blocked arteries just as accurately for patients with chest pain.
Mar 30, 2026
Immediate revascularization tied to higher 1-year risk in STEMI with multivessel disease and heart failure
Cardiology RCT
Immediate revascularization tied to higher 1-year risk in STEMI with multivessel disease and heart failure For heart attack patients with heart failure, does fixing all blockages right away help or hurt?
In the OPTION-STEMI trial, immediate complete revascularization was not non-inferior to staged revascularization.
For heart attack patients with heart failure, fixing all blockages immediately raises the risk of death or another heart attack within a yea…
Mar 30, 2026

Questions about myocardial ischemia

Can a sirolimus-eluting iron bioresorbable scaffold treat coronary artery disease patients with myocardial ischemia?

A 2024 trial found that a sirolimus-eluting iron bioresorbable scaffold did not perform as well as standard metallic stents for treating coronary artery disease in patients with myocardial ischemia.

Full answer →
Which stent type shows better results for patients with myocardial ischemia in the Chinese trial?

A 2024 Chinese trial found that everolimus-eluting stents resulted in less late lumen loss compared to a new iron bioresorbable scaffold in patients with myocardial ischemia.

Full answer →
Does a sirolimus-eluting iron scaffold cause more late lumen loss than everolimus stents for myocardial ischemia?

Yes, the sirolimus-eluting iron scaffold (IBS) showed higher late lumen loss than the everolimus-eluting stent at 2 years in the IRONMAN-II trial.

Full answer →